Devyser Diagnostics AB has secured a CFTR NGS proposal with UNC Hospitals. The proposal with UNC Hospitals is valid for a period of up to four years. Indicative order value is estimated to be approximately SEK 2.5 million annually.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
110 SEK | 0.00% | -0.90% | +39.95% |
May. 30 | Devyser Wins Tender for Oncology NGS Solutions in Italy | CI |
May. 27 | Devyser Wins Tender for Thalassemia in Italy | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+39.95% | 171M | |
+49.99% | 56.95B | |
+39.98% | 40.26B | |
-6.94% | 39.32B | |
-4.42% | 28.37B | |
+11.88% | 26.45B | |
-18.12% | 19.41B | |
+30.17% | 12.54B | |
+25.29% | 12.21B | |
+0.04% | 12.15B |
- Stock Market
- Equities
- DVYSR Stock
- News Devyser Diagnostics AB
- Devyser Diagnostics AB Achieves Breakthrough in the US with Cystic Fibrosis NGS Test